alendronate has been researched along with Episcleritis in 6 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We report a case of orbital and ocular inflammation secondary to the use of intravenous zoledronic acid and a case of scleritis secondary to oral alendronate." | 4.12 | [Bisphosphonate-induced ocular and orbital inflammation]. ( Funding, M; Jakobsen, TS, 2022) |
| "The alendronate was discontinued, and, with the administration of prednisone, the symptoms of scleritis fully resolved." | 2.43 | Bisphosphonate-associated scleritis: a case report and review. ( Ashar, BH; Leung, S; Miller, RG, 2005) |
| "Uveitis and scleritis are the most serious ocular side effects of bisphosphonate therapy." | 1.35 | Postmarketing surveillance rates of uveitis and scleritis with bisphosphonates among a national veteran cohort. ( French, DD; Margo, CE, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Jakobsen, TS | 1 |
| Funding, M | 1 |
| Samalia, P | 1 |
| Sims, J | 1 |
| Niederer, R | 1 |
| French, DD | 1 |
| Margo, CE | 1 |
| Fraunfelder, FW | 1 |
| Winthrop, K | 1 |
| Suhler, E | 1 |
| Choi, D | 1 |
| Fraunfelder, FT | 1 |
| Leung, S | 1 |
| Ashar, BH | 1 |
| Miller, RG | 1 |
| Mbekeani, JN | 1 |
| Slamovits, TL | 1 |
| Schwartz, BH | 1 |
| Sauer, HL | 1 |
1 review available for alendronate and Episcleritis
| Article | Year |
|---|---|
Bisphosphonate-associated scleritis: a case report and review.
Topics: Aged; Aged, 80 and over; Alendronate; Diphosphonates; Female; Humans; Osteoporosis, Postmenopausal; | 2005 |
5 other studies available for alendronate and Episcleritis
| Article | Year |
|---|---|
[Bisphosphonate-induced ocular and orbital inflammation].
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Humans; Inflammation; Scleritis | 2022 |
Drug-induced ocular inflammation.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alendronate; Allopurinol; Anti-Inflammatory Agents, Non- | 2020 |
Postmarketing surveillance rates of uveitis and scleritis with bisphosphonates among a national veteran cohort.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Databa | 2008 |
Postmarketing surveillance rates of uveitis and scleritis with bisphosphonates among a national veteran cohort.
Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Databases, Factual; Diphosphona | 2009 |
Ocular inflammation associated with alendronate therapy.
Topics: Aged; Alendronate; Endophthalmitis; Female; Humans; Middle Aged; Myositis; Scleritis | 1999 |